December 1 Is Bard's Next PowerPort Court Date: the Missouri Infection Claim and What Two Split Verdicts Mean for Filers

On December 1, 2026, a Missouri woman's infection claim against Bard goes to trial in Arizona, the fourth test trial in the PowerPort litigation. It follows a defense verdict and a $40 million plaintiff win, so what this jury decides will shape settlement talks for thousands of pending cases.

Key Facts

  • 4,140 federal PowerPort cases were pending on October 1, 2026, up from 3,734 in September, according to the Judicial Panel's docket report.
  • May 8, 2026: the first test trial ended with a partial defense verdict and a hung jury on the design-defect claim.
  • September 4, 2026: a Phoenix jury awarded Kimberly Divelbliss $40 million in compensatory damages, the litigation's first plaintiff win.
  • October 13, 2026: the third test trial, an infection case from Florida, opened with a trial window running through October 30.
  • December 1, 2026: the fourth test trial, Judy Hicks of Missouri, alleges an infection and blood clot that required two surgeries to remove the port.

A Bard PowerPort is a small implanted port placed under the skin to give long-term intravenous access for chemotherapy, blood draws, or medication. A multidistrict litigation, usually shortened to MDL, is a procedure that groups similar federal cases before one judge for pretrial work while each case stays individual.

Two Trials, Two Answers

The federal PowerPort cases are consolidated as MDL No. 3081 before Judge David G. Campbell in the District of Arizona. The first test trial, heard in May 2026, involved an infection claim and ended with a partial defense verdict: the jury rejected the warning claims and deadlocked on whether the design itself was defective. The second, heard in August and decided on September 4, 2026, could hardly have been more different. Kimberly Divelbliss of New Mexico had been implanted with a PowerPort in 2017; about two years later, its Groshong silicone catheter fractured, a fragment lodged in her heart, and she needed removal surgery followed by treatment for cardiac arrhythmias and heart attacks. A nine-person jury found unanimously for Divelbliss on strict-liability and negligent design-defect claims and on strict-liability and negligent failure-to-warn claims, awarding $40 million in compensatory damages. The jury declined to find fraudulent concealment and awarded no punitive damages. That verdict, a specific award in a named case, is the litigation's first substantial plaintiff recovery, and it reset every conversation about what these cases might be worth at trial. Compensation varies widely by case, and no verdict in one case fixes the value of another.

The Missouri Claim at the Center of December 1

The December 1 trial belongs to Judy Hicks of Missouri. Her claim, like the first trial's, centers on infection, but with an added complication: she alleges the port caused an infection and a blood clot that required two surgeries to remove the device. That combination matters because it lets the jury hear both the infection theory that deadlocked in the first trial and the kind of concrete, procedure-by-procedure harm story that carried the second. The court set the trial on October 15, 2026, as the third trial was getting underway, and held a final pretrial conference on October 26. A fifth test trial is already calendared for February 2, 2027. Hicks does not need to prove that every PowerPort is defective; she needs to prove, on her own medical record, that the design or the warnings failed her and that the failure caused her infection, clot, and surgeries.

What the October Orders Changed

October was a month of quiet rulings with loud consequences. On September 25, the court had already denied Bard's request to end the Florida infection case before trial, holding that it could not call the PowerPort's warnings adequate as a matter of law, and it allowed the punitive-damages claim to proceed to a second phase if liability is found. In mid-October, the judge then limited what one defense expert may testify about in the December trial, narrowing the evidence Bard can offer on the issues that expert covers. Meanwhile the third trial, brought by May Lattanzio of Florida, opened on October 13 with a window running through October 30: she received her port in 2013 and alleges a bloodstream infection that required surgery to remove it. Its two-phase structure means the jury decides liability first and reaches punitive damages only if it finds Bard liable. No verdict in that trial had been reported as this article was written, and no outcome should be assumed before the jury speaks.

What Happens After the December Trial

Three paths follow December, and filers should understand all three. If Hicks wins, pressure for a broad resolution rises, because Bard would then have lost two of the last three test trials on different injury theories. If Bard wins, the defense will argue that Divelbliss was the exception, a fracture case with unusually dramatic proof, and that infection claims remain hard to win. Either way, a fifth trial in February 2027 keeps the calendar moving, and if no broad resolution is reached once the test trials conclude, the judge could begin sending cases back to their home districts for individual trial dates. No global settlement of the PowerPort litigation has been announced, and most settlements, when they come, are confidential. The docket itself keeps growing: 4,140 federal cases were pending on October 1, 2026, up from 3,734 a month earlier, a sign that new filers are still arriving even as the test trials play out. Readers who want plain-language explainers on related legal and money topics can visit the Problem Solved channel.

Who Benefits From This — and Who Does Not

People with a Bard implanted port who developed an infection, a fracture or migration, a blood clot, or a blockage benefit directly from watching Hicks, because her infection-plus-clot facts resemble the most common complications. Patients still living with a port and noticing fever, swelling, pain at the site, or difficulty drawing blood benefit from the warning signs these trials publicize, since early medical attention protects both health and any later claim. Families of patients who needed removal surgery, like the Florida infection case now in trial, benefit from seeing how removal and treatment records are presented to a jury. People who do not benefit include those whose port never caused a problem, those with a different manufacturer's device, and those whose complications trace to their illness or treatment rather than the device itself. A trial verdict also does not, on its own, pay anyone else: each claimant still needs their own medical proof and their own filing. The earlier port-infection lawsuit involving a different device shows the same lesson from another angle: device, records, and causation decide the case, not the headline.

What to Check Before You Act

Do not wait for December to organize your file. Confirm the exact device from your implant record, since Bard PowerPort cases turn on the specific catheter model. Collect the operative report, every infection or clot diagnosis, and the removal surgery notes, because gaps in that chain are the first thing defense lawyers attack. Note your state's filing deadline and the date you first connected the device to the injury, since device cases raise difficult discovery questions about when the clock started. Finally, read the October update on the $40 million verdict and the 4,140 pending cases alongside this article so you compare your facts against all three test trials, not just the one that makes the news.

Frequently Asked Questions

Who benefits from following the December 1 PowerPort trial?

People with an implanted Bard port who suffered an infection, fracture, migration, or blood clot benefit most, because the Hicks trial tests the infection theory that applies to their own facts. Families weighing whether to file also benefit: the verdicts so far show which arguments persuaded a jury and which did not.

Who does not benefit from this trial, or for whom is it not enough on its own?

People whose port caused no complication do not benefit from a trial about injuries they did not suffer, and no verdict in another person's case decides their claim. Anyone whose device is a different brand, or whose injury came from the underlying illness rather than the device, should not read this trial as covering their situation.

How do I benefit, and how do I start if I think I have a claim?

Start with three concrete steps. First, gather your implant record, operative report, and any removal or infection treatment records. Second, write down the dates of implantation, symptoms, and every procedure in order. Third, ask a lawyer who handles device cases to review those records against the Hicks and Divelbliss fact patterns before any filing deadline in your state passes.

What exactly is a bellwether trial?

A bellwether trial is a representative test case chosen from a large group of similar lawsuits. Its verdict does not decide other cases, but both sides use it to judge how juries react and what settlements might look like.

Why did the first two PowerPort trials come out differently?

The first trial, an infection case, ended with a defense verdict on the warning claims and a hung jury on design defect, while the second, a catheter-fracture case, produced a unanimous $40 million award on design-defect and failure-to-warn claims. Different injuries, different proof, and different juries explain the split better than any single theory.

Has Bard recalled the PowerPort?

No. Bard's parent company has said the device is cleared by regulators and has not been recalled over the fracture issue, which is precisely why the claims proceed as lawsuits rather than as a recall program.

This article is general information only and is not legal or medical advice. Laws, deadlines, and medical decisions depend on individual facts; consult a qualified lawyer and your treating physician about your own situation.

Watch on YouTube

Problem Solved on YouTube